A plethora of biomaterials for heart repair are being tested worldwide for potential clinical application. These therapeutics aim to enhance the quality of life of patients with heart disease using various methods to improve cardiac function. Despite the myriad of therapeutics tested, only a minority of these studied biomaterials have entered clinical trials. This rapid scoping review aims to analyze literature available from 2012 to 2022 with a focus on clinical trials using biomaterials for direct cardiac repair, , where the intended function of the biomaterial is to enhance the repair of the endocardium, myocardium, epicardium or pericardium. This review included neither biomaterials related to stents and valve repair nor biomaterials serving as vehicles for the delivery of drugs. Surprisingly, the literature search revealed that only 8 different biomaterials mentioned in 23 different studies out of 7038 documents (journal articles, conference abstracts or clinical trial entries) have been tested in clinical trials since 2012. All of these, intended to treat various forms of ischaemic heart disease (heart failure, myocardial infarction), were of natural origin and most used direct injections as their delivery method. This review thus reveals notable gaps between groups of biomaterials tested pre-clinically and clinically. Rapid scoping review of clinical application of biomaterials for cardiac repair. 7038 documents screened; 23 studies mention 8 different biomaterials only. Biomaterials for repair of endocardium, myocardium, epicardium or pericardium. Only 8 different biomaterials entered clinical trials in the past 10 years. All of the clinically translated biomaterials were of natural origin.

中文翻译：

---

用于直接心脏修复的生物材料——2012-2022年快速范围界定审查

全球范围内正在测试大量用于心脏修复的生物材料，以寻求潜在的临床应用。这些疗法旨在通过各种方法改善心脏功能来提高心脏病患者的生活质量。尽管测试了无数的治疗方法，但这些研究的生物材料中只有少数进入了临床试验。本快速范围审查旨在分析 2012 年至 2022 年可用的文献，重点是使用生物材料进行直接心脏修复的临床试验，其中生物材料的预期功能是增强心内膜、心肌、心外膜或心包的修复。该综述既不包括与支架和瓣膜修复相关的生物材料，也不包括用作药物输送载体的生物材料。令人惊讶的是，文献检索显示，自 2012 年以来，在 7038 篇文献（期刊文章、会议摘要或临床试验条目）中，只有 23 项不同研究中提到的 8 种不同的生物材料经过了临床试验。所有这些，旨在治疗各种形式的缺血性心脏病（心力衰竭、心肌梗塞）是自然起源的，大多数使用直接注射作为治疗方法。因此，本综述揭示了临床前和临床测试的生物材料组之间的显着差距。心脏修复生物材料临床应用的快速范围审查。筛选了7038份文件； 23 项研究仅提及 8 种不同的生物材料。用于修复心内膜、心肌、心外膜或心包膜的生物材料。过去10年只有8种不同的生物材料进入临床试验。所有临床转化的生物材料都是天然来源的。